Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 11 of 11 publications.
Skip to main content
Gilsenan A, Harding A, Kellier-Steele N, Harris D, Midkiff K, Andrews E. The Forteo patient registry linkage to multiple state cancer registries: study design and results from the first 8 years. Osteoporos Int. 2018 Oct;29(10):2335-43. doi: 10.1007/s00198-018-4604-8
Auth D, Gilsenan A, Morrato E, Smith M, Wise L. Effective risk management: best practices for designing, implementing and evaluating risk minimization programs. Presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2018. Prague, Czech Republic.
Krueger WS, Young JC, Hollis K, Hauber AB, Gilsenan A, Ritchey ME. Limitations in reporting "benefit-risk" across therapeutic areas in medical device literature. Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):515. doi: 10.1002/pds.4629
Harris D, Midkiff K, Gilsenan A, Andrews E. Linking big (federal) data to state cancer registry data for a post-marketing drug safety surveillance study: challenges and lessons learned. Presented at the 2018 Annual Conference of the North American Association of Central Cancer Registries (NAACCR); June 12, 2018. Pittsburgh, PA.
Gilsenan A, Fortuny J, Plana E, Ruigomez A, Karlsson P, Flynn RWV, Cantero OF, Garcia-Rodriguez L, Linner L, Cainzos-Achirica M, Bartsch J, MacDonald T, Kieler H, Andrews EB. Non-interventional cohort study of the relative incidence of major cardiovascular events among patients initiating prucalopride versus a matched comparator cohort initiating polyethylene glycol 3350 (PEG). Poster presented at the 2018 Digestive Disease Week; June 3, 2018. Washington, DC.
Ritchey ME, Hollis KA, Hauber AB, Gilsenan A, Krueger WS. Reporting of "Benefit-Risk" studies for medical devices in published literature. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 23, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S175. doi: 10.1016/j.jval.2018.04.1167
Stanford RH, Gilsenan AW, Lincourt W, Lankevich C, Ortega H. Status of asthma control in primary care in the US: results from the asthma control characteristics and prevalence survey study (ACCESS). Presented at the American College of Asthma Allergy and Immunology Annual Meeting; November 2008.
Lincourt W, Stanford RH, Gilsenan AW, Lankevich C, Vanderpuije A, Ortega H. Status of asthma control in pediatric practices in the US: results from the asthma control characteristics and prevalence survey study (ACCESS). Poster presented at the American College of Nurse Practitioner Meeting; October 2008.
Gilsenan AW, Ladner A, Varas-Lorenzo C, Kold Olesen T, Karup C, Andrews EB. Incidence of cardiovascular and cerebrovascular events among men with prostate cancer. Poster presented at the 24th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 9, 2008. Copenhagen, Denmark.
Andrews EB, Irish WD, Gilsenan AW, Campbell WH. Evaluation of therapeutic risk management programs. In: Hartzema AG, Tilson HH, Arnold Chan K, editors. Pharmacoepidemiology and therapeutic risk management. 1st ed. Cincinnati: United States. Harvey Whitney Books; 2008. p.637-52.
Andrews EB, Gilsenan AW, Cook SF. Therapeutic risk management interventions: feasibility and effectiveness. In: Pharmacoepidemiology and therapeutic risk management. Cincinnati: United States. Harvey Whitney Books; 2008. p.613-33.